Home2024-05-16T14:31:12+04:00

The countdown to the 14th AdARRC has begun – mark your calendars!

0
0
0
0
Days
0
0
Hours
0
0
Minutes
0
0
Seconds
Add to Calendar

ADARRC’s Decade of Education, Innovation & Action

14 years, 7 months, 24 days

ADARRC ACADEMIC BREAKING NEWS

Monday Weekly Updates

STAY CONNECTED

@adarrcrheuma
  • Dive into this week's intriguing clinical query! Test your knowledge with our quiz. 
Are you up for the challenge? Click the link to embark on your learning journey! https://bit.ly/3K5JZoG 

#ClinicalQuery #MedicalQuiz #ChallengeAccepted #ADARRC #QOTW
  • Take the first step towards enhancing your rheumatology knowledge and networking with industry experts by registering early for #ADARRC2024! Don't miss this opportunity to secure your spot at the premier event in advanced rheumatology education. Register now and be ahead of the curve!
  • Share your groundbreaking research with us at #ADARRC2024! Whether you're exploring new frontiers or presenting innovative solutions, we want to hear from you. Submit your abstract today and be part of the conversation shaping the future of #Rheumatology. #CallForAbstracts #Research #Innovation
  • Question of the week: 
Which one of the following first-line therapies should be provided after pericardiocentesis in a 20-year-old man presenting with a first episode of a new large pericardial effusion, symptoms of acute pericarditis, an elevated erythrocyte sedimentation rate, and no risk factors for tuberculosis?

https://rb.gy/1ivzad
  • ADARRC wishes you and your loved ones a joyful, happy, and blessed Eid! 🌙
  • ADARRC wishes you and your loved ones a blessed Ramadan 🌙
  • Clinical Question: Does the monoclonal antibody sarilumab facilitate the tapering of glucocorticoid therapy in patients with polymyalgia rheumatica?

Bottom Line: Giving patients with PMR sarilumab twice monthly for 1 year allows an accelerated tapering regimen that greatly reduces the cumulative steroid dose and increases the likelihood of remission (which was low in both groups). Neutropenia, diarrhea, and arthralgia were common adverse effects. The annual drug cost is estimated to be $18,400. The cost per additional sustained response is more than $90,000, and it is unclear what the value is of the lower cumulative dose of prednisone. 

Reference: https://bit.ly/49hHs5k
  • May the blessings and prosperity of the coming year brighten the path of you and your loved ones.

#HappyNewYear from ADARRC!
  • Relive the Best of ADARRC 2023🌟

Thank you for participating in the 13th edition of ADARRC. Your enthusiasm and dedication made this event a great success. We can't wait to see you next year! 

#ADARRC2023 #MedicalEducation #SeeYouNextYear
Dive into this week's intriguing clinical query! Test your knowledge with our quiz. 
Are you up for the challenge? Click the link to embark on your learning journey! https://bit.ly/3K5JZoG 

#ClinicalQuery #MedicalQuiz #ChallengeAccepted #ADARRC #QOTW
Dive into this week's intriguing clinical query! Test your knowledge with our quiz. Are you up for the challenge? Click the link to embark on your learning journey! https://bit.ly/3K5JZoG #ClinicalQuery #MedicalQuiz #ChallengeAccepted #ADARRC #QOTW
5 days ago
View on Instagram |
1/9
Take the first step towards enhancing your rheumatology knowledge and networking with industry experts by registering early for #ADARRC2024! Don't miss this opportunity to secure your spot at the premier event in advanced rheumatology education. Register now and be ahead of the curve!
Take the first step towards enhancing your rheumatology knowledge and networking with industry experts by registering early for #ADARRC2024! Don't miss this opportunity to secure your spot at the premier event in advanced rheumatology education. Register now and be ahead of the curve!
1 week ago
View on Instagram |
2/9
Share your groundbreaking research with us at #ADARRC2024! Whether you're exploring new frontiers or presenting innovative solutions, we want to hear from you. Submit your abstract today and be part of the conversation shaping the future of #Rheumatology. #CallForAbstracts #Research #Innovation
Share your groundbreaking research with us at #ADARRC2024! Whether you're exploring new frontiers or presenting innovative solutions, we want to hear from you. Submit your abstract today and be part of the conversation shaping the future of #Rheumatology. #CallForAbstracts #Research #Innovation
3 weeks ago
View on Instagram |
3/9
Question of the week: 
Which one of the following first-line therapies should be provided after pericardiocentesis in a 20-year-old man presenting with a first episode of a new large pericardial effusion, symptoms of acute pericarditis, an elevated erythrocyte sedimentation rate, and no risk factors for tuberculosis?

https://rb.gy/1ivzad
Question of the week: Which one of the following first-line therapies should be provided after pericardiocentesis in a 20-year-old man presenting with a first episode of a new large pericardial effusion, symptoms of acute pericarditis, an elevated erythrocyte sedimentation rate, and no risk factors for tuberculosis? https://rb.gy/1ivzad
1 month ago
View on Instagram |
4/9
ADARRC wishes you and your loved ones a joyful, happy, and blessed Eid! 🌙
2 months ago
View on Instagram |
5/9
ADARRC wishes you and your loved ones a blessed Ramadan 🌙
2 months ago
View on Instagram |
6/9
Clinical Question: Does the monoclonal antibody sarilumab facilitate the tapering of glucocorticoid therapy in patients with polymyalgia rheumatica?

Bottom Line: Giving patients with PMR sarilumab twice monthly for 1 year allows an accelerated tapering regimen that greatly reduces the cumulative steroid dose and increases the likelihood of remission (which was low in both groups). Neutropenia, diarrhea, and arthralgia were common adverse effects. The annual drug cost is estimated to be $18,400. The cost per additional sustained response is more than $90,000, and it is unclear what the value is of the lower cumulative dose of prednisone. 

Reference: https://bit.ly/49hHs5k
Clinical Question: Does the monoclonal antibody sarilumab facilitate the tapering of glucocorticoid therapy in patients with polymyalgia rheumatica? Bottom Line: Giving patients with PMR sarilumab twice monthly for 1 year allows an accelerated tapering regimen that greatly reduces the cumulative steroid dose and increases the likelihood of remission (which was low in both groups). Neutropenia, diarrhea, and arthralgia were common adverse effects. The annual drug cost is estimated to be $18,400. The cost per additional sustained response is more than $90,000, and it is unclear what the value is of the lower cumulative dose of prednisone. Reference: https://bit.ly/49hHs5k
4 months ago
View on Instagram |
7/9
May the blessings and prosperity of the coming year brighten the path of you and your loved ones.

#HappyNewYear from ADARRC!
May the blessings and prosperity of the coming year brighten the path of you and your loved ones. #HappyNewYear from ADARRC!
5 months ago
View on Instagram |
8/9
Relive the Best of ADARRC 2023🌟 Thank you for participating in the 13th edition of ADARRC. Your enthusiasm and dedication made this event a great success. We can't wait to see you next year! #ADARRC2023 #MedicalEducation #SeeYouNextYear
7 months ago
View on Instagram |
9/9
Go to Top